

PANCREASE* Capsules deliver PANCREATIN BP the full dose of enzyme right to the site of digestion.



PANCREASE* – the only enteric coated microsphere preparation.

- Protected from gastric inactivation
- Improves nutritional status
- Effective in Cystic Fibrosis and Chronic Pancreatic Insufficiency.

PRESCRIBING INFORMATION – PANCREASE* Capsules

Presentation: Hard white gelatin capsules containing enteric coated beads of pancreatin BP. Each capsule has a protease activity of not less than 330 BP Units and amylase activity of not less than 2,900 BP Units and lipase activity of not less than 5,000 BP Units. **Uses:** Exocrine pancreatic enzyme deficiency. **Dosage and administration:** For adults and children 1 or 2 capsules during each meal and one capsule with snacks. To protect the enteric coating the beads should not be crushed or chewed. **Contra-indications, warnings, etc.** Hypersensitivity to pork protein. The safety of Pancrease* during pregnancy has not yet been established. Such use is not recommended. The most frequently reported adverse reactions to Pancrease* Capsules are gastrointestinal in nature. Contact of the beads with food having a pH higher than 5.5 can dissolve the protective enteric shell. **Pharmaceutical precautions:** Keep bottle tightly closed. Store at room temperature in a dry place. Do not refrigerate.

Legal category: P **Package Quantities:** Containers of 100 capsules.

Basic NHS Cost: £15.98 (for 100 capsules). **Product Licence Number:** PL 76/129.



Further information available from:
Ortho Cilag Pharmaceutical Ltd.,
PO. Box 79, Saunderton,
High Wycombe, Bucks. HP14 4HU

The
MEMOIR
Club

**The BMJ's new series of books of
general interest by medical writers**

Not Always on the Level by E J Moran Campbell. Romantic memories of a Yorkshire childhood; hilarious ones of student days in London; a detailed and fascinating account of Campbell's pioneering work in respiratory physiology; and a painfully honest description of what it is like to be a manic depressive.

Price: Inland £14.95; Abroad £18.50; U.S.A.\$30.00
BMA members: Inland £13.95; Abroad £17.50;
U.S.A.\$28.00

Recollections and Reflections by Douglas Black, who recalls episodes from his remarkable career—in which he has been professor of medicine at Manchester University, chief scientist at the DHSS, and president of the Royal College of Physicians—and reflects on the practice and progress of medicine, university teaching and administration, public service, and life in general.

Price: Inland £14.95; Abroad £17.50; U.S.A.\$29.00
BMA members: Inland £13.95; Abroad £16.50;
U.S.A.\$27.00

Doctors in Science and Society by Christopher Booth, who examines the lives and times of some eighteenth century medical scientists and the role of their present day successors. A must for anyone interested in the past and future of medical science.

Price: Inland £14.95; Abroad £19.50; U.S.A.\$32.00
BMA members: Inland £13.95; Abroad £18.50;
U.S.A.\$30.00

All prices include postage, by air abroad
Please enclose payment with order

ORDER FROM: British Medical Journal
PO Box 295, London WC1H 9TE
or any leading medical bookseller



Insulin with a future

In 1922, Lilly led the world in insulin technology when their co-operation with Banting and Best resulted in the first large scale production of insulin.

Lilly is still the world's largest manufacturer of insulin.

Lilly was the first to manufacture insulin by genetic engineering — technology which assures future supplies of insulin.

The first genetically engineered human insulin



Humulin
Human Insulin (prb)

NEW

**ALLERGIC TO COW'S MILK?
INFANTS NEED
THE COMPLETE ANSWER.**

FARLEY'S OSTERSOY

- Milk and lactose free.
- Sucrose free.
- Added taurine and carnitine.
- Vegetarian.
- Meets DHSS and Codex nutrient levels for infant formulas.

THE COMPLETE SOYA PROTEIN FORMULA.

IMPORTANT NOTICE Breast milk is best for babies. OsterSoy milk-free formula is intended to meet the nutritional needs of infants and children who are allergic to cow's milk protein or intolerant to lactose. Professional advice should be followed.

For samples and full product information, please write to:
Farley Health Products Limited, 1 Thane Road West, Nottingham NG2 3AA.



An associate company of




NOCTURNAL ENURESIS?

Dry nights start with **DESMOSPRAY**[®] DESMOPRESSIN NASAL SPRAY

The new physiological approach to Nocturnal Enuresis

Recent information indicates that bedwetters with primary nocturnal enuresis may produce excessive volumes of urine overnight owing to inadequate nocturnal levels of vasopressin (antidiuretic hormone). **DESMOSPRAY** at bedtime can correct this overnight polyuria, by supplementing the patients' own ADH with **DESMOPRESSIN**, the established vasopressin analogue with enhanced antidiuretic activity. **DESMOSPRAY** sprayed into each nostril at bedtime is usually sufficient to control bedwetting in this large group of sufferers, leading to dry nights.



ABRIDGED PRESCRIBING INFORMATION

Presentation: Metered dose pre-compression atomiser delivering 10 micrograms Desmopressin per spray. **Uses:** Desmopressin is a structural analogue of the natural antidiuretic hormone vasopressin, with increased antidiuretic activity and prolonged duration of action. The pressor activity is greatly reduced as a result of which side-effects are rarely seen. **INDICATIONS and DOSAGE:** Primary Nocturnal Enuresis Adults and children from 5 years of age: one spray in each nostril (20 micrograms) at bedtime. The dose may be increased up to 2 sprays in each nostril (40 micrograms) if the lower dose is not sufficiently effective. The treatment should not be prescribed for more than 28 days. **Treatment of Diabetes Insipidus:** The average maintenance dose in adults and children is one or two sprays (10 to 20 micrograms) once or twice daily. **Contra-indications:** When used to control Primary Nocturnal Enuresis **DESMOSPRAY** should only be used in patients with normal blood pressure. **Precautions:** **DESMOSPRAY** should be used with caution in pregnant patients although the oxytocic effect is very low. Care should be taken with patients who have reduced renal function and/or cardiovascular disease. Fluid overload should be avoided and patients should only take as much fluid as required to satisfy thirst. **Legal category:** POM **Package quantity:** 5 ml bottle **Basic N.H.S. Price:** £19.92 PL No. 3194/0024 PL Holder: Ferring Pharmaceuticals Ltd. 11 Mount Road, Feltham, Middlesex TW13 6JG **DESMOSPRAY** is a trademark.

Further information is available and should be consulted before prescribing - Ferring Pharmaceuticals Ltd. 11 Mount Road, Feltham, Middlesex TW13 6JG

FERRING
PHARMACEUTICALS

PRESCRIBING INFORMATION

HUMAN VELOSULIN® (Neutral Insulin Injection, human insulin (emp)). HUMAN INSULATARD® (Isophane Insulin Injection (NPH), human insulin (emp)). HUMAN MIXTARD® 30/70 (Neutral Suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection (NPH), human insulin (emp)). HUMAN INITARD® 50/50 (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection (NPH), human insulin (emp)). **Presentation** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10 ml. vials containing 100 iu/ml. To aid identification the metal sealing rings of the vials have tactile marks as follows: Human Velosulin – one mark; Human Insulatard – two marks; Human Mixtard 30/70 – three marks; Human Initard 50/50 – four marks. The vials are fitted with tamper-evident caps. **Uses** The treatment of insulin-requiring diabetes. **Dosage and Administration** The dosage of insulin is determined by the physician according to the needs of the patient. Human Velosulin may be given by s.c., i.m., or i.v. injection. Human Insulatard, Human Mixtard 30/70 and Human-Initard 50/50 should be re-suspended by inverting the vial several times before being given by s.c. or i.m. injection (they must not be given intravenously). Intermixing does not affect the characteristics of any of these insulins. **Use in pregnancy:** Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Use in the elderly:** Insulin may have a more prolonged action due to reduced clearance rate. **Contra-indications warnings etc. Contra-indications:** Hypoglycaemia. **Precautions:** Patients transferring from other insulins may require a dosage adjustment. Concomitant therapy with thyroxine, corticosteroids, oral contraceptives, diuretics, beta blockers and M.A.O.I.s may affect insulin requirements. **Side and Adverse Effects:** Hypoglycaemia. Local reactions, lipodystrophy and hypersensitivity reactions are rarely reported with human insulins. **Pharmaceutical Precautions** be used. **Legal Category P. Package Quantities** 10 ml. glass vials. **Basic NHS Price** Human Insulatard 3132/0034; Human Mixtard 30/70 3132/0037; Human Initard 50/50 Insulatard 0003/0212; Human Mixtard 30/70 0003/0213; Human Initard 50/50 0003/0214. House, Garland Court, Garland Road, East Grinstead, West Sussex RH19 1DN. Foundation Ltd, Crewe Hall, Crewe, Cheshire CW1 1UB. Tel: Crewe (0270) 583151.



Store between 2-8°C, protected from sunlight. Insulin which has been frozen should not be used. **Product Licence Numbers** NORDISK-UK: Human Velosulin 3132/003 3132/0040. THE WELLCOME FOUNDATION LTD: Human Velosulin 0003/0211; Human Insulatard 0003/0212; Human Mixtard 30/70 0003/0213; Human Initard 50/50 0003/0214. Further information is available on request from either: Nordisk-UK, Nordisk House, East Grinstead (0342) 410373, or Wellcome Medical Division, The Wellcome Foundation Ltd, Beckenham, Kent (0342) 410373. **Reference** I. Heine RJ, et al. Diabetologia, 1984; 27: 558-562. *Registered Trade Mark



designed for each other..

HUMAN VELOSULIN®
Human neutral soluble insulin (emp)

HUMAN INSULATARD®
Human isophane (NPH) insulin (emp)

Quick and intermediate acting insulins developed to be compatible.

No interaction when mixed.!

Predictable effect in individually titrated regimens.